Table 1. Characteristics of the trials included in the meta-analysis.
| Characteristics of Patients in Constituent Trials | ||||||||
|---|---|---|---|---|---|---|---|---|
| Research orientation | Phase | Cancer type | Treatment | Median PFS (months) | Female/Patients(No.) | Age in years, Madian(range) | PD-L1 positive/ negative |
BRAF mutation/ wild-type |
| Weber J.S 2015 | III | melanoma | Nivolumab 3mg/kg every 2 weeks | 4.7 | 96(272) | 59(23-88) | 134/138 | 60/212 |
| Chemotherapy | 4.2 | 48(133) | 62(29-85) | 29/66 | 29/104 | |||
| Larkin.J 2015 | III | melanoma | Nivolumab 3mg/kg every 2 weeks | 6.9 | 114(316) | 59(25-90) | 80/208 | 100/316 |
| Nivolumab 1mg/kg every 3 weeks + Ipilimumab 3mg/kg every 2 weeks | 11.5 | 108(314) | 59(18-88) | 68/210 | 101/213 | |||
| Ipilimumab | 2.9 | 113(315) | 61(18-89) | 75/202 | 97/218 | |||
| Robert.C 2015 | III | melanoma | Pembrolizumab 3mg/kg every 2 weeks | 5.5 | 118(279) | 61(18-89) | 225/54 | 98/181 |
| Pembrolizumab 3mg/kg every 3 weeks | 4.1 | 103(277) | 63(22-89) | 221/56 | 97/180 | |||
| Ipilimumab | 2.8 | 116(278) | 62(18-88) | 225/53 | 107/171 | |||
| Brahmer.J 2015 | III | NSCLC | Nivolumab 3mg/kg every 2 weeks | 3.5 | 24(135) | 62(39-85) | NA | NA |
| Docetaxel | 2.8 | 49(137) | 64(42-84) | NA | NA | |||
| Robert.C 2014 | III | melanoma | Nivolumab 3mg/kg every 2 weeks | 5.1 | 89(210) | 64(18-86) | 74/136 | 0/202 |
| Dacarbazine | 2.2 | 83(208) | 66(26-87) | 74/134 | 0/204 | |||
| Ribas.A 2015 | II | melanoma | Pembrolizumab 2mg/kg every 2 weeks | 5.4 | 76(180) | 62(15-87) | NA | 44/136 |
| Pembrolizumab 10mg/kg every 3 weeks | 5.8 | 72(181) | 60(27-89) | NA | 40/141 | |||
| Chemotherapy | 3.6 | 65(179) | 63(27-87) | NA | 41/138 | |||
| Postow MA 2015 | I | melanoma | Nivolumab 1mg/kg every 3 weeks + Ipilimumab 3mg/kg every 2 weeks | NA | 32(95) | 64(27-87) | NA | 23/72 |
| Ipilimumab | 4.4 | 15(47) | 67(31-80) | NA | 10/37 | |||
| Borghaei.H 2015 | III | NSCLC | Nivolumab 3mg/kg every 2 weeks | 2.3 | 141(292) | 61(37-84) | NA | NA |
| Docetaxel | 4.2 | 122(290) | 64(21-85) | NA | NA | |||
| Motzer R.J 2015 | III | Renal-cell Carcinoma | Nivolumab 3mg/kg every 2 weeks | 4.6 | 95(410) | 107(411) | NA | NA |
| Everolimus | 4.4 | 62(411) | 62(18-86) | NA | NA | |||
| Fehrenbacher.L 2016 | II | NSCLC | Atezolizumab 1200mg/m2 every 3weeks | 2.7 | 51(144) | 62(42-82) | 96/48 | NA |
| Docetaxel | 3 | 67(143) | 61(36-84) | 82/61 | NA | |||
NSCLC: Non-Small-Cell Lung Cancer; NA: not available; PFS: Progression-free survival